IE-IR Research Engineer

OverviewInstitut Curie is a major player in the research and fight against cancer. It consists of a Hospital Group and a Research Center of more than 1000 employees with a strong international objective of the Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.LaboratoryThe research group DNA repair mechanisms in cancers (Ceccaldi Lab, is seeking an engineer (IE or IR) driving cutting-edge research projects aiming at understanding the mechanisms regulating genome stability.In the recent years, our team significant contributions to the field of genome stability and tumor biology. Focusing on compensatory mechanisms employed by cancer cells with defects in homologous recombination (HR)-mediated repair, we shed light on new mechanisms and pathways controlling genome stability and Homologous Recombination (HR)-deficient tumor survival.From a translational point of view, our group has identified (and developed inhibitors against) new drug targets for the treatment of breast and ovarian tumors target and highlighted the importance of studying the relationships between the different DNA repair pathways to better understand their interaction and exploit them for therapeutic purposes. Our long-term research goals hinge on the critical need for 1) new scientific approaches to discover additional regulators and effectors of genome stability, 2) basic understanding of interconnections between DNA repair processes, and 3) new drug development and biomarkers for anticancer targeted therapy.Recent publication from the team1. Zhou, J. et al. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nature Cancer, 2021.2. Gelot, C. et al. Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis. Nature, 2023.9. Kovacs, M. T. et al. DNA damage induces nuclear envelope rupture through ATR-mediated phosphorylation of lamin A / C. Molecular Cell, 2023.8. Musiani, D. et al. SMUG1 trapping at unprocessed uracil upon UNG inhibition triggers homologous recombination and selectively kills BRCA1 / 2-deficient tumors. In revision, 2024.MissionsThe applicant will work on a project aiming at deciphering the molecular mechanism(s) of mitotic repair. The applicant will work closely with a PhD student and a postdoctoral fellow and conduct experiments including :CloningProtein purification (E. Coli, Insect cells)Protein-protein interaction assayMicroscopyQualificationsProspective applicants should have a master or degree in molecular biology or biochemistry. The ideal applicant has further expertise in biochemistry or super-resolution microscopy. Great communication skills are needed, together with appropriate organizational capacity.Professional English and / or French level required.All our opportunities are open to people with disabilitiesContract and BenefitsType of contract : Fixed-term contractStarting date : As soon as possibleDuration : 3 yearsWorking time : full time - number of days – 39 hours per weekRemuneration : according to the current gridsBenefits : Collective catering, reimbursement of transportation fees up to 70%, supplementary health insuranceLocation of the position : ParisContactPlease send your application including your CV, a letter of motivation explaining why you would like to join our team and contact information of at least two referees.Publication date : 07th of May 2024Deadline for application : 31st of July 2024Institut Curie is an inclusive, equal opportunity employer and is dedicated to the highest standards of research integrity. #J-18808-Ljbffr